Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research32

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research32

FiltersClear all

Status

Recruiting9
Active, not recruiting11
Completed7
Terminated5

Study type

Interventional27
Expanded access5

Phase

Phase 110
Phase 37
Phase 1/26
Not reported5
Phase 24

Investigator

Ruben Niesvizky19
Mateo Mejia Saldarriaga6
Roger N Pearse3
Victor Hugo Jimenez Zepeda2
Alexandra Gomez Arteaga1

Department

Medicine32

Condition

Multiple Myeloma32
Prostatic Neoplasms52
Leukemia, Myeloid, Acute50
Breast Neoplasms43
Heart Failure34

Show all 50

Intervention type

Drug31
Biological2
Procedure1

Sponsor type

Industry28
Other academic2
NIH1
WCM (investigator-initiated)1

Start date

Has results posted6

Multiple Myeloma×Clear all

Showing 1–20 of 32 studiesSort:

Active, not recruitingInterventional · Phase 1/2NCT02773030 ↗
Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 As Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma
Ruben NiesvizkyPI
Intervention
Drug: CC-220 · Drug: Dexamethasone · Drug: Daratumumab · Drug: Bortezomib · Drug: Carfilzomib · Drug: Daratumumab - 16mg/kg · Drug: Bortezomib (BTZ) · Drug: Daratumumab- 1800mg

FiltersClear all

Status

Recruiting9
Active, not recruiting11
Completed7
Terminated5

Study type

Interventional27
Expanded access5

Phase

Phase 110
Phase 37
Phase 1/26
Not reported5
Phase 24

Investigator

Ruben Niesvizky19
Mateo Mejia Saldarriaga6
Roger N Pearse3
Victor Hugo Jimenez Zepeda2
Alexandra Gomez Arteaga1

Department

Medicine32

Condition

Multiple Myeloma32
Prostatic Neoplasms52
Leukemia, Myeloid, Acute50
Breast Neoplasms43
Heart Failure34

Show all 50

Intervention type

Drug31
Biological2
Procedure1

Sponsor type

Industry28
Other academic2
NIH1
WCM (investigator-initiated)1

Start date

Has results posted6

Multiple Myeloma×Clear all

Showing 1–20 of 32 studiesSort:

Active, not recruitingInterventional · Phase 1/2NCT02773030 ↗
Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 As Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma
Ruben NiesvizkyPI
Intervention
Drug: CC-220 · Drug: Dexamethasone · Drug: Daratumumab · Drug: Bortezomib · Drug: Carfilzomib · Drug: Daratumumab - 16mg/kg · Drug: Bortezomib (BTZ) · Drug: Daratumumab- 1800mg

Show all 6

Show fewer

Gail J Roboz1

Show fewer

Neoplasms32
Colitis, Ulcerative29
Atrial Fibrillation27
Carcinoma, Non-Small-Cell Lung27
Crohn Disease27
Recurrence27
COVID-1926
Myelodysplastic Syndromes26
Parkinson Disease24
Neoplasm Metastasis23
Obesity23
Colorectal Neoplasms19
HIV Infections19
Hematologic Neoplasms19
Cardiovascular Diseases18
Depression18
Non-alcoholic Fatty Liver Disease16
Overweight15
Lung Neoplasms14
Melanoma14
Cognitive Dysfunction13
Idiopathic Pulmonary Fibrosis13
Inflammatory Bowel Diseases13
Alzheimer Disease12
Leukemia12
Leukemia, Lymphocytic, Chronic, B-Cell12
Lymphoma, Non-Hodgkin12
Primary Myelofibrosis12
Coronary Artery Disease11
Hypertension11
Hypertension, Pulmonary11
Lung Diseases, Interstitial11
Myeloproliferative Disorders11
Pulmonary Arterial Hypertension11
Stroke11
Chronic Pain10
Hemophilia A10
Leukemia, Myelomonocytic, Chronic10
Lymphoma, Follicular10
Lymphoma, Large B-Cell, Diffuse10
Urinary Bladder Neoplasms10
Burkitt Lymphoma9
Fibrosis9
Liver Diseases9
Carcinoma, Renal Cell8

Dates

Oct 2016 – May 2024· Results posted

Sponsor

Celgene Corporation

Multiple Myeloma

Active, not recruitingInterventional · Phase 1NCT03091257 ↗

An Open-label, Pilot Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma

Ruben NiesvizkyPI

Intervention: Drug: Dabrafenib · Drug: Trametinib
Dates: Jun 2017 – Jul 2026
Sponsor: Dana-Farber Cancer Institute

Multiple Myeloma

Active, not recruitingInterventional · Phase 2NCT04302324 ↗

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

Mateo Mejia SaldarriagaPI

Intervention: Drug: Daratumumab SC · Drug: Clarithromycin · Drug: Pomalidomide · Drug: Dexamethasone
Dates: Oct 2021 – May 2024· Results posted
Sponsor: Weill Medical College of Cornell University

Multiple MyelomaRefractory Multiple MyelomaRelapse Multiple Myeloma

Active, not recruitingInterventional · Phase 1NCT04722146 ↗

A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Ruben NiesvizkyPI

Intervention: Drug: Teclistamab · Drug: Daratumumab · Drug: Pomalidomide · Drug: Lenalidomide · Drug: Bortezomib · Drug: Nirogacestat
Dates: Mar 2021 – Oct 2025
Sponsor: Janssen Research & Development, LLC

Multiple Myeloma

RecruitingExpanded accessNCT04771078 ↗

Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

Roger N PearsePI

Intervention: Biological: Nonconforming idecabtagene vicleucel
Dates: Started Sep 2021
Sponsor: Celgene Corporation

Multiple Myeloma

Active, not recruitingInterventional · Phase 3NCT04923893 ↗

A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Roger N PearsePI

Intervention: Drug: Bortezomib · Drug: Dexamethasone · Drug: Lenalidomide · Drug: Cilta-cel · Drug: Cyclophosphamide · Drug: Fludarabine
Dates: Aug 2021 – Feb 2029 (est.)
Sponsor: Janssen Research & Development, LLC

Multiple Myeloma

RecruitingInterventional · Phase 1/2NCT04973605 ↗

A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)

Ruben NiesvizkyPI

Intervention: Drug: Sonrotoclax · Drug: Dexamethasone · Drug: Carfilzomib · Drug: Daratumumab · Drug: Pomalidomide
Dates: Sep 2021 – Nov 2026 (est.)
Sponsor: BeiGene USA

Relapsed/Refractory Multiple Myeloma

Active, not recruitingInterventional · Phase 1NCT05050097 ↗

A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Ruben NiesvizkyPI

Intervention: Drug: Talquetamab · Drug: Carfilzomib · Drug: Daratumumab SC · Drug: Lenalidomide · Drug: Pomalidomide
Dates: Sep 2021 – Mar 2025
Sponsor: Janssen Research & Development, LLC

Multiple Myeloma

RecruitingInterventional · Phase 1NCT05137054 ↗

Phase 1b Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Patients With Relapsed/Refractory Multiple Myeloma

Ruben NiesvizkyPI

Intervention: Drug: Linvoseltamab · Drug: Daratumumab · Drug: Carfilzomib · Drug: Lenalidomide · Drug: Bortezomib · Drug: Pomalidomide · Drug: Isatuximab · Drug: Fianlimab · Drug: Cemiplimab · Drug: Nirogacestat · Drug: Cevostamab
Dates: Aug 2022 – Mar 2028 (est.)
Sponsor: Regeneron Pharmaceuticals, Inc.

Multiple Myeloma

RecruitingExpanded accessNCT05346835 ↗

Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma

Ruben NiesvizkyPI

Intervention: Drug: Cilta-cel OOS Therapy
Dates: Started Jul 2022
Sponsor: Janssen Scientific Affairs, LLC

Multiple Myeloma

Active, not recruitingInterventional · Phase 2NCT05354557 ↗

Phase II Multicenter Trial of Iberdomide as Maintenance Therapy for Multiple Myeloma Patients With Sub-Optimal Response After Autologous Hematopoietic Cell Transplantation or After Salvage Autologous Hematopoietic Cell Transplantation

Alexandra Gomez ArteagaPI

Intervention: Drug: Iberdomide
Dates: Apr 2022 – Apr 2027 (est.)
Sponsor: Memorial Sloan Kettering Cancer Center

Multiple Myeloma

RecruitingInterventional · Phase 3NCT05552222 ↗

A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy

Victor Hugo Jimenez ZepedaPI

Intervention: Drug: Teclistamab · Drug: Daratumumab · Drug: Lenalidomide · Drug: Dexamethasone · Drug: Talquetamab
Dates: Oct 2022 – Apr 2031 (est.)
Sponsor: Janssen Research & Development, LLC

Multiple Myeloma

Active, not recruitingInterventional · Phase 1NCT05688475 ↗

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating CC-122

Ruben NiesvizkyPI

Intervention: Drug: CC-122 · Drug: Dexamethasone
Dates: Apr 2023 – Nov 2026 (est.)
Sponsor: Celgene Corporation

Non-Hodgkin Lymphoma

RecruitingInterventional · Phase 1/2NCT06119685 ↗

Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Mateo Mejia SaldarriagaPI

Intervention: Drug: IDP-023 · Drug: Rituximab · Drug: Daratumumab · Drug: Interleukin-2 · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Mesna · Drug: Isatuximab
Dates: Oct 2023 – Dec 2025 (est.)
Sponsor: Indapta Therapeutics, Inc.

NHLMultiple MyelomaBlood Cancer+4 more

Active, not recruitingInterventional · Phase 2NCT06169215 ↗

A Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Diagnosed Multiple Myeloma

Mateo Mejia SaldarriagaPI

Intervention: Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration · Procedure: Bone Marrow Biopsy · Drug: Bortezomib · Procedure: Computed Tomography · Drug: Daratumumab and Recombinant Human Hyaluronidase · Drug: Dexamethasone · Drug: Lenalidomide · Procedure: Magnetic Resonance Imaging · Procedure: Positron Emission Tomography · Drug: Selinexor
Dates: Jul 2024 – Apr 2026
Sponsor: National Cancer Institute

Multiple Myeloma

Active, not recruitingInterventional · Phase 3NCT06208150 ↗

64407564MMY3009: A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pom

Ruben NiesvizkyPI

Intervention: Drug: Talquetamab · Drug: Pomalidomide · Drug: Teclistamab · Drug: Elotuzumab · Drug: Dexamethasone · Drug: Bortezomib
Dates: Jan 2024 – Apr 2026
Sponsor: Janssen Research & Development, LLC

Multiple Myeloma

Active, not recruitingInterventional · Phase 3NCT06413498 ↗

A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma

Victor Hugo Jimenez ZepedaPI

Intervention: Drug: Anitocabtagene Autoleucel · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Pomalidomide · Drug: Bortezomib · Drug: Dexamethasone · Drug: Daratumumab · Drug: Carfilzomib
Dates: Aug 2024 – Jul 2028 (est.)
Sponsor: Kite Pharma, Inc.

Multiple Myeloma

RecruitingInterventional · Phase 3NCT06615479 ↗

A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma

Mateo Mejia SaldarriagaPI

Intervention: Drug: BMS-986393 · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Daratumumab · Drug: Pomalidomide · Drug: Dexamethasone · Drug: Carfilzomib
Dates: Mar 2025 – Dec 2027 (est.)
Sponsor: Juno Therapeutics, Inc.

Relapsed or Refractory Multiple Myeloma (RRMM)

RecruitingInterventional · Phase 3NCT06679101 ↗

A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

Mateo Mejia SaldarriagaPI

Intervention: Drug: Belantamab mafodotin · Drug: Lenalidomide · Drug: Dexamethasone · Drug: Daratumumab
Dates: Dec 2024 – Apr 2031 (est.)
Sponsor: GlaxoSmithKline

Multiple MyelomaNewly Diagnosed Multiple Myeloma

RecruitingInterventional · Phase 1/2NCT06892522 ↗

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of T Cell Engaging Bi/Tri-specific Antibodies in Subjects With MM

Mateo Mejia SaldarriagaPI

Intervention: Drug: Etentamig · Drug: Lenalidomide · Drug: Dexamethasone · Drug: Daratumumab · Drug: Carfilzomib · Drug: Mezigdomide · Drug: Iberdomide · Drug: ABBV-2001 · Drug: Pomalidomide
Dates: Jun 2025 – Dec 2035 (est.)
Sponsor: AbbVie Inc.

Multiple Myeloma

‹ Prev1 2 Next ›